HC Wainwright Weighs in on Lineage Cell Therapeutics Q1 Earnings

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) – Analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Lineage Cell Therapeutics in a report released on Tuesday, March 11th. HC Wainwright analyst J. Pantginis forecasts that the company will post earnings per share of ($0.01) for the quarter. HC Wainwright currently has a “Buy” rating and a $9.00 price objective on the stock. The consensus estimate for Lineage Cell Therapeutics’ current full-year earnings is ($0.12) per share. HC Wainwright also issued estimates for Lineage Cell Therapeutics’ Q2 2025 earnings at ($0.01) EPS, Q3 2025 earnings at ($0.01) EPS, Q4 2025 earnings at ($0.02) EPS and FY2025 earnings at ($0.06) EPS.

Other research analysts have also issued reports about the stock. D. Boral Capital reissued a “buy” rating and set a $2.00 target price on shares of Lineage Cell Therapeutics in a research note on Tuesday. Maxim Group dropped their target price on shares of Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a report on Friday, January 10th.

Lineage Cell Therapeutics Price Performance

LCTX opened at $0.52 on Thursday. The business has a 50-day moving average of $0.60. The company has a market cap of $114.66 million, a P/E ratio of -4.34 and a beta of 1.21. Lineage Cell Therapeutics has a 1-year low of $0.48 and a 1-year high of $1.61.

Institutional Trading of Lineage Cell Therapeutics

Several large investors have recently made changes to their positions in the company. Alyeska Investment Group L.P. acquired a new stake in shares of Lineage Cell Therapeutics during the fourth quarter worth $1,984,000. Renaissance Technologies LLC raised its position in shares of Lineage Cell Therapeutics by 1,058.3% in the fourth quarter. Renaissance Technologies LLC now owns 2,283,072 shares of the company’s stock valued at $1,147,000 after purchasing an additional 2,085,972 shares during the period. DAFNA Capital Management LLC grew its stake in Lineage Cell Therapeutics by 85.9% during the fourth quarter. DAFNA Capital Management LLC now owns 2,511,374 shares of the company’s stock valued at $1,262,000 after acquiring an additional 1,160,666 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in Lineage Cell Therapeutics during the fourth quarter valued at approximately $519,000. Finally, Raffles Associates LP grew its stake in Lineage Cell Therapeutics by 21.8% during the fourth quarter. Raffles Associates LP now owns 5,492,088 shares of the company’s stock valued at $2,760,000 after acquiring an additional 984,307 shares in the last quarter. Institutional investors and hedge funds own 62.47% of the company’s stock.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.